UDJ Stock Overview
A biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Applied DNA Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.66 |
| 52 Week High | US$33.22 |
| 52 Week Low | US$4.66 |
| Beta | 0.25 |
| 1 Month Change | -24.72% |
| 3 Month Change | -57.40% |
| 1 Year Change | -77.75% |
| 3 Year Change | -95.19% |
| 5 Year Change | -98.73% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| UDJ | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | 0.6% |
| 1Y | -77.7% | -9.1% | 5.4% |
Return vs Industry: UDJ underperformed the German Life Sciences industry which returned -9.1% over the past year.
Return vs Market: UDJ underperformed the German Market which returned 5.4% over the past year.
Price Volatility
| UDJ volatility | |
|---|---|
| UDJ Average Weekly Movement | 15.4% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: UDJ's share price has been volatile over the past 3 months.
Volatility Over Time: UDJ's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 54 | James Hayward | www.adnas.com |
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics.
Applied DNA Sciences, Inc. Fundamentals Summary
| UDJ fundamental statistics | |
|---|---|
| Market cap | €2.19m |
| Earnings (TTM) | -€11.53m |
| Revenue (TTM) | €5.09m |
0.4x
P/S Ratio-0.2x
P/E RatioIs UDJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UDJ income statement (TTM) | |
|---|---|
| Revenue | US$5.52m |
| Cost of Revenue | US$3.64m |
| Gross Profit | US$1.88m |
| Other Expenses | US$14.38m |
| Earnings | -US$12.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.49 |
| Gross Margin | 33.98% |
| Net Profit Margin | -226.55% |
| Debt/Equity Ratio | 0% |
How did UDJ perform over the long term?
See historical performance and comparison